KBC Securities - ArGEN-X SE (ARGX) argenx FIRST LOOK: 3Q24 results beat consensus, reach operating profitability

Report

KBC Securities

Jacob Mekhael

argenx FIRST LOOK: 3Q24 results beat consensus, reach operating profitability

argenx reported a strong quarter with Vyvgart sales coming in at $ 573m, 8% above BBG analyst consensus, showcasing the robustness of the company's commercial engine. We note that the company reached operating profitability for the quarter despite increased investments in R&D and SG&A. In the pipeline, timelines are reiterated and we look ahead to the upcoming go/no go decision for myositis by YE24 and an update on the BP study. We reiterate our Accumulate and € 530.

31/10/2024 1 EN

Underlying

ArGEN-X SE

Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.

See profile

NL0010832176 Euronext Brussels Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

Oddo BHF

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/31/2024

...

20h / 51m 20h / 51m 1 EN

Oddo BHF

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 31/10/2024

...

21h / 15m 21h / 15m 1 FR

Oddo BHF

Argenx : An excellent Q3 2024 beating expectations. Target price raised to € 580

>Forecasts beaten for sales and EBIT - Q3 sales were up by 74% y-o-y and 34% q-o-q to $ 573m (US $ 492m, Japan $ 24m, EMEA $ 46m and $ 11m supply in China), reflecting both strong demand for products (i.e. Vyvgart and Vyvgart Hytrulo) and excellent commercial execution. Note that this quarter includes CIPD sales for the first time. The group provides no information on the breakdown by indication but indicates that the launch of this new indication “got off to an impr...

22h / 10m 22h / 10m 1 EN

Galapagos 9M24 conference call feedback

Galapagos hosted a conference call to discuss its 9M24 results. Most noteworthy is that we learned of an R&D day panned for 2025, as well as the deal structure with the company's CAR-T manufacturing partners in the US. We summarise the main takeaways below.

17h / 32m 17h / 32m 1 EN

Wim Hoste

Wim Hoste

DSM-Firmenich Conference call feedback

Below are the highlights from the 3Q results conference call. 3Q adjusted EBITDA jumped 32% and beat our and consensus by respectively 3% and 1%. Dsm-firmenich increased FY24 adj EBITDA guidance from c € 2bn to towards € 2.1bn, citing disruption in the vitamin market. We remind that the recently announced mid term financial targets for the new scope (ie ex ANH) are similar to the targets of the current group, ie 5-7% organic sales growth and an 22-23% adjusted EBITDA margin, which represent a sizeable step-up to the FY23 margin level of c. 18% (ex ANH). We believe that the recent vitamin price...

21h / 27m 21h / 27m 1 EN

Wim Hoste

Wim Hoste

Recticel FIRST LOOK: 3Q LFL revenue growth +6%, FY guidance maintained

3Q revenue growth accelerated to 6% on a like for like basis, with revenue of € 156.6m slightly above our and consensus forecasts. Recticel reiterated its FY guidance of around € 50m adjusted EBITDA. Although we do believe in the longer term growth prospects of the insulation market, short term multiples are not particularly appealing with EV/EBITDA25e of c 10x and so we reiterate our Hold rating for now.

22h / 25m 22h / 25m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

argenx FIRST LOOK: 3Q24 results beat consensus, reach operating profitability

We are a financial services provider for several types of professional clients, each with distinct needs.

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/31/2024

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 31/10/2024

Argenx : An excellent Q3 2024 beating expectations. Target price raised to € 580

Galapagos 9M24 conference call feedback

DSM-Firmenich Conference call feedback

Recticel FIRST LOOK: 3Q LFL revenue growth +6%, FY guidance maintained

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe